2003年9月由美国Cubist公司研制的抗菌药达托霉素(1)获得美国FDA批准,用于治疗革兰阳性菌引起的复杂皮肤感染、结构性皮肤感染。随后,美国和欧盟又批准了其新的临床适应证:心脏感染和菌血症等。2009年9月1日在我国批准上市,商品名为克必信,用于金黄色葡萄球菌导致的伴发右侧感染性心内膜炎的血流感染[1,2]。文献报道的HPLC法多是适用于测定发酵液样品中的1[3,4]。本 Daptomycin (1), an antibacterial drug developed by the Cubist Company in the United States in September 2003, has been approved by the U.S. FDA for the treatment of complex skin infections and structural skin infections caused by Gram-positive bacteria. Subsequently, the United States and the European Union also approved its new clinical indications: heart infections and bacteremia. September 1, 2009 approved the listing in our country, the product name Kebixin, for Staphylococcus aureus caused by infection with the right side of the infectious endocarditis bloodstream infections [1,2]. The HPLC method reported in the literature is suitable for the determination of fermentation broth samples 1 [3,4]. this